Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer

Xiaoli Wei(Anhui Medical University), Rui‐Hua Xu(Sun Yat-sen University), Jianing Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Feng‐Hua Wang(Sun Yat-sen University), Chao Ren(Sun Yat-sen University), Dongliang Chen(Central South University), De‐Shen Wang(Sun Yat-sen University), Jianying Xu(LMU Klinikum), Feng Wang(Sun Yat-sen University)
Therapeutic Advances in Medical Oncology
January 1, 2021
10.1177/1758835921988996
Cited by 39

Related Papers

Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868
Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization
|Advanced Materials|2017|756
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657